## AMENDMENTS TO THE CLAIMS

Complete Listing of the Claims:

Claims 1, 10, 11 and 12 are currently amended claims.

Claims 2, 3, 4, 6, 7, 8, 9, 16 and 17 are cancelled.

Claim 13 is an original claim.

Claims 14-16 are non-elected claims.

Claims 18-24 are newly added claims.

- 1. (Currently Amended) A <u>catheter having an outer surface and said outer surface having an</u> highly lubricious hydrophilic coating for a medical device comprising: a mixture of colloidal aliphatic polyurethane, an aqueous dilution of PVP and dendrimers selected from the group consisting of: poly(amidoamine dendrimers, poly(propylene imine) dendrimers, polyether\_dendrimers, phenlyacetylene dendrimers, chiral dendrimers, and tecto dendrimers, to enhance the physical integrity of the coating, to improve adhesion and to covalently bind or load an agent <u>selected from the group consisting essentially of: an anti-thrombotic drug, heparin, sodium heparin, an antibiotic or a dye, within the dendrimer structure.</u>
- 2. (Cancelled) The coating of claim 1 wherein the agent is an antithrombolitic drug.
  - 3. (Cancelled) The coating of claim 1 wherein the agent is an antibiotic.
  - 4. (Cancelled) The coating of claim 1 wherein the agent is a dye.
- 5. (Currently Amended) The <u>catheter</u> <del>coating</del> of claim 1 <del>comprising</del> <u>wherein</u> <u>said coating comprises</u> a colloidal dispersion of an aliphatic polyurethane polymer in a solvent mixture including:

an aliphatic polyurethane polymer;

purified water;

N-methyl-2 pyrrolidone;

dendrimers;

poly (1-vinylpyrrolidone-co-2-diamethylamino ethyl methacrylate)-PVP triethylamine; and,

said agent.

6. (Cancelled) The coating of claim 5 wherein the agent is an antithrombolitic drug.

- 7. (Cancelled) The coating of claim 5 wherein the antithrombolitic drug is sodium heparin.
- 8. (Cancelled) The coating of claim 5 wherein the agent is an antibiotic drug.
  - 9. (Cancelled) The coating of claim 5 wherein the agent is a dye.
- 10. (Currently amended) A method for applying the coating of claim 1 to a medical device the catheter comprising the step of dipping the medical device catheter into a solution containing the mixture of colloidal aliphatic polyurethane, the aqueous dilution of PVP and the dendrimers.
- 11. (Currently amended) A method for applying the coating of claim 1 to a medical device the catheter comprising the step of airless spraying of the medical device catheter with a solution containing the mixture of colloidal aliphatic polyurethane, the aqueous dilution of PVP and the dendrimers.
- 12. (Currently amended) A method for applying the coating of claim 1 to a the catheter comprising the step of dipping the catheter into a solution containing the mixture of colloidal aliphatic polyurethane, the aqueous dilution of PVP and the dendrimers.
- 13. (Original) The method of claim 12 further including the step of flushing a lumen of the catheter with nitrogen during the dipping process to prevent the solution from entering the catheter's lumen.
- 14. (Non-elected and Currently Amended) A medical device catheter coated, in a first zone where the medical device catheter contacts blood, with a first hydrophilic coating containing one of an eluting anti-thrombogenic drug and/or a dye, and coated, in a second zone, where the medical device catheter comes in contact with tissue, with a second hydrophilic coating containing one of an eluting antibiotic drug and/or a dye.
- 15. (Non-elected and Currently amended) The medical device catheter of claim 14 wherein each hydrophilic coating comprises a mixture of colloidal aliphatic polyurethane, an aqueous dilution of PVP and dendrimers to enhance the physical integrity of the coating, to improve adhesion and to covalently bind or load with one of either the anti-thrombolitic drug, or the antibiotic drug or the dye.
  - 16. (Cancelled) The medical device of claim 14 being a catheter.
- 17. (Cancelled) The coating of claim 2 wherein said antithrombolitic drug is sodium heparin.

- 18. (New) A guidewire having an outer surface and said outer surface having an highly lubricious hydrophilic coating comprising: a mixture of colloidal aliphatic polyurethane, an aqueous dilution of PVP and dendrimers selected from the group consisting of: poly(amidoamine dendrimers, poly(propylene imine) dendrimers, polyether\_dendrimers, phenlyacetylene dendrimers, chiral dendrimers, and tecto dendrimers, to enhance the physical integrity of the coating, to improve adhesion and to covalently bind or load an agent selected from the group consisting essentially of: an anti-thrombotic drug, heparin, sodium heparin, an antibiotic or a dye, within the dendrimer structure.
- 19. (New) The guidewire of claim 18 wherein said coating comprises a colloidal dispersion of an aliphatic polyurethane polymer in a solvent mixture including:

an aliphatic polyurethane polymer;

purified water;

N-methyl-2 pyrrolidone;

dendrimers;

poly (1-vinylpyrrolidone-co-2-diamethylamino ethyl methacrylate)-PVP triethylamine; and,

said agent.

- 20. (New) A method for applying the coating of claim 18 to a guidewire comprising the step of dipping the guidewire into a solution containing the mixture of colloidal aliphatic polyurethane, the aqueous dilution of PVP and the dendrimers.
- 21. (New) A method for applying the coating of claim 18 to the guidewire comprising the step of airless spraying of the guidewire with a solution containing the mixture of colloidal aliphatic polyurethane, the aqueous dilution of PVP and the dendrimers.
- 22. (New) A method for applying the coating of claim 18 to the guidewire comprising the step of dipping the guidewire into a solution containing the mixture of colloidal aliphatic polyurethane, the aqueous dilution of PVP and the dendrimers.
- 23. (New) A guidwire coated, in a first zone where the guidewire contacts blood, with a first hydrophilic coating containing one of an eluting anti-thrombogenic drug or a dye, and coated, in a second zone, where the guidewire

comes in contact with tissue, with a second hydrophilic coating containing one of an eluting antibiotic drug or a dye.

24. (New) The guidewire of claim 23 wherein each hydrophilic coating comprises a mixture of colloidal aliphatic polyurethane, an aqueous dilution of PVP and dendrimers to enhance the physical integrity of the coating, to improve adhesion and to covalently bind or load with one of the anti-thrombolitic drug, the antibiotic drug or the dye.